started · updated
Andalusian study shows monoclonal antibody reduces RSV hospitalizations
Researchers in Andalusia, Spain, have confirmed that the administration of the monoclonal antibody nirsevimab significantly reduces hospitalizations caused by respiratory syncytial virus (RSV) in infants. The multicenter study, which included the University Hospital of Jaén and eight other pediatric hospitals in the region, indicates that the protective benefits extend into the child's second year of life.
While previous evidence focused on preventing severe illness during the immediate season of administration, this new research, published in the journal Pediatrics, shows that infants who received the dose during the 2023-2024 season saw an estimated 17% absolute reduction in hospitalizations for lower respiratory tract infections during the 2024-2025 season. The reduction was even more pronounced in cases specifically positive for RSV, showing a 25.4% decrease, and reached 27.7% among minors with a history of inhaler use.
Entities
Andalusia · Ibima · Pediatrics · University Hospital of Jaén